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BACKGROUND: A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed
to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to
those of patients living without obesity.
METHODS: We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from
Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually
exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or
death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and
death) by obesity status.
RESULTS: We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816)
hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8−40.0)
than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0−33.2). In both cohorts, PLWO were more often female.
Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical
conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to
COVID-19 patients without obesity.
CONCLUSION: We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with
more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help
guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.
International Journal of Obesity; https://doi.org/10.1038/s41366-021-00893-4
INTRODUCTION
Obesity is associated with increased mortality and is a well-known
risk factor for chronic conditions, such as diabetes, hypertension,
cardiovascular disease, and cancer [1, 2]. Due to its proinflamma-
tory state that impairs the immune response, obesity has also
been related to an increased risk of viral infections [3]. The novel
coronavirus disease 2019 (COVID-19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in
December 2019 in Wuhan, China, and rapidly spread around the
world [4]. This new virus causes a respiratory tract infection with
clinical manifestations ranging from asymptomatic/mild symp-
toms to severe illness requiring intensive services. Partly due to its
similarities with other viral infections such as seasonal influenza or
H1N1, people with obesity were soon labeled as “at-risk”
individuals [5]. Since obesity is a worldwide public health priority,
granular information on patients with COVID-19 and obesity is
needed to guide preventive strategies as well as to generate
hypotheses for etiological studies [6].
A review and meta-analysis of 75 studies reported that obesity
is a risk factor for testing positive for SARS-CoV-2, for severe
COVID-19 and for COVID-19 related mortality [7]. While undoubt-
edly relevant to the field, these studies mainly focused on
exploring multiple risk factors related to COVID-19 and thus did
not offer a detailed characterization of patients with COVID-19
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living with obesity. For instance, an exhaustive description of the
medical conditions and COVID-19 related outcomes, such as
thromboembolic events, among these patients is lacking. Other
current limitations include the susceptibility to collider bias of
studies reporting “risk factors” of COVID-19 infection and
progression due to sampling mechanisms (e.g., subsamples of
tested or hospitalized populations) [8]. A large characterization
study focussing exclusively on patients with COVID-19 living with
obesity using real-world data from different health settings and
countries could address the limitations of the previous evidence.
In this study, we aimed to describe and compare the
demographics, medical conditions, and outcomes of COVID-19
patients living with obesity (PLWO) to those of COVID-19 patients
living without obesity, in inpatient or outpatient settings.
METHODS
Study design, setting, and data sources
We conducted a multinational cohort study using routinely collected
healthcare data from January to June 2020 from Spain, the United
Kingdom (UK), and the United States (US). This study was part of the
“Characterizing Health Associated Risks, and Your Baseline Disease In
SARS-COV-2 (CHARYBDIS)” study (protocol available for download
at https://www.ohdsi.org/wp-content/uploads/2020/07/Protocol_COVID-
19-Charybdis-Characterisation_V5.docx) designed by the Observational
Health Data Sciences and Informatics (OHDSI) community. All data were
standardized to the Observational Medical Outcomes Partnership
(OMOP) Common Data Model (CDM) [9]. The OHDSI network maintains
the OMOP-CDM, along with a wide range of tools developed by its
members to facilitate analyses of mapped data [10]. Data results for this
study were extracted on July, 16th, 2020.
We included primary, outpatient and inpatient care data from electronic
health records (EHRs) and health insurance claims data from six databases.
Data from Spain included the Information System for Research in Primary
Care (SIDIAP), which includes primary linked to inpatient care data
covering approximately 80% of the population in Catalonia, Spain [11]. The
UK data covered the Clinical Practice Research Datalink (CPRD), with
patients from over 600 general practices in the UK [12]. Data from the US
included: Columbia University Irving Medical Center (CUIMC), covering
New York-Presbyterian Hospital and its affiliated physician practices; IQVIA
Open Claims, which are pre-adjudicated claims collected from office-based
physicians and specialists covering over 300 million lives (~80% of the US
population); the Stanford Medicine Research Data Repository (STARR-
OMOP), with data from Stanford Health Care [13], and the United States
Department of Veterans Affairs (VA-OMOP), covering the national
Department of Veterans Affairs health care system which serves more
than 9 million enrolled Veterans (of whom 93% are male). A more detailed
description of the included data sources is available in Supplementary
Appendix 1.
Study participants
We included two non-mutually exclusive cohorts of patients: (1) all patients
diagnosed with COVID-19 (clinical diagnosis and/or positive test for SARS-
CoV-2), and (2) all patients hospitalized with a COVID-19 diagnosis. We
considered clinical diagnoses in the definition of COVID-19 cases due to
testing restrictions during the first months of the pandemic (e.g., in Spain)
[14]. The diagnostic codes used are described in Supplementary Appendix
2. Patients hospitalized with COVID-19 were identified as those having a
hospitalization episode along with a clinical diagnosis or positive SARS-
CoV-2 test within a time window from 21 days prior to admission up to the
end of their hospitalization. We chose this time window to include patients
with a diagnosis prior to hospitalization and to allow for a record delay in
test results or diagnoses [15]. We included individuals with at least one
year of observation time prior to the index date to capture observed
baseline characteristics. In the diagnosed cohort, the index date was
defined as the date of the COVID-19 clinical diagnosis or the earliest test
day registered within seven days of a first positive test, whichever occurred
first. In the hospitalized cohort, the index date was the day of
hospitalization. Patients were followed from the index date to the earliest
of death, end of the observation period, or 30 days [16].
Both the diagnosed and hospitalized COVID-19 cohorts were stratified by
obesity status: PLWO vs patients living without obesity (from now on,
referred to as patients without obesity). Obesity was defined as having an
ever-recorded obesity diagnosis (Supplementary Appendix 3) and/or a
body mass index (BMI) measurement between 30 and 60 kg/m2 and/or a
bodyweight measurement between 120 and 200 kg prior or at index date.
We included upper cut-off thresholds to discard implausible observations.
Patients without obesity were those who did not fulfill the obesity
definition.
Baseline characteristics and outcomes of interest
Demographics (sex and age) were obtained at the index date. More than
15 000 medical conditions from up to one year prior to the index date
were identified based on the Systematized Nomenclature of Medicine
(SNOMED) hierarchy, with all descendant codes included [15]. Specific
definitions for comorbidities of particular interest were created; the
detailed definitions of these variables can be consulted in Supplementary
Appendix 3. We reported here a list of key comorbidities based on their
prevalence in the cohorts of the participating sites, as well as on their
clinical relevance to obesity and the COVID-19 research field [17].
Our 30-day outcomes of interest for the diagnosed cohort were
hospitalization and fatality. For the hospitalized cohort, the 30-days
outcomes were a requirement of intensive services (IS) (identified by a
recorded mechanical ventilation and/or a tracheostomy and/or extra-
corporeal membrane oxygenation procedure), respiratory, cardiovascular,
thromboembolic, and other events and fatality.
Data analysis
We described the number of patients included and the prevalence of
obesity in each database as well as the demographics, comorbidities, and
outcomes as proportions (calculated by the number of persons within a
given category, divided by the total number of persons) with their
respective 95% confidence intervals (CIs) for each database, by obesity
status. To calculate these proportions in each database, we established a
minimum count required (of five individuals), to minimize the risk of re-
identification of patients. To compare medical conditions across groups,
we calculated standardized mean differences (SMDs) [18], which we
summarized in Manhattan-style plots. The SMD can be used to compare
the prevalence of a dichotomous variable between two groups and is
independent of sample size [19]. A |SMD| > 0.1 indicates a meaningful
difference in the prevalence of a given condition; in the context of this
study, a SMD > 0.1 indicates a higher prevalence in PLWO, whereas a
SMD <−0.1 indicates a higher prevalence among patients without obesity.
This study was descriptive by nature and, therefore, statistical modeling
was out of scope. Differences across the groups compared should not be
interpreted as causal effects.
To ensure data privacy at all times, we employed a federated analysis
approach [16]. Following a pre-specified analysis plan, a common
analytical code for the whole CHARYBDIS study was developed for the
OHDSI Methods library, available at https://github.com/ohdsi-studies/
Covid19CharacterizationCharybdis, and was run locally in each data-
base. Individual-level data remained within host institutions and only
aggregate results from each database were provided to the research
team and publicly shared. All the results reported in this paper and
additional data are available for consultation at a dynamic and
interactive website, which changes over time as new databases are
added and/or results are updated to CHARYBDIS (https://data.ohdsi.org/
Covid19CharacterizationCharybdis/).
We used R version 3.6 for data visualization. All the data partners
obtained Institutional Review Board (IRB) approval or exemption to
conduct this descriptive study.
RESULTS
Prevalence of obesity
We included 627 044 diagnosed and 160 013 hospitalized patients
with COVID-19 (Table 1). The diagnosed cohort consisted of 122
058 patients from Spain (SIDIAP), 2336 from the UK (CPRD), and
502 650 from the US (CUIMC: 8519; IQVIA-OpenClaims: 466 191;
STARR-OMOP: 3328; VA-OMOP: 24 612). The hospitalized cohort
included 18 197 patients from Spain (SIDIAP) and 141 816 from
the US (CUIMC: 2600; IQVIA-OpenClaims: 133 091; STARR-OMOP:
615; VA-OMOP: 5510). Among diagnosed and hospitalized patients,
207 859 (33.1%; 95%CI: 33.0−33.2) and 63 866 (39.9%, 95%CI: 39.8
−40.0) had obesity, respectively. In all databases, the prevalence
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of obesity was lower among diagnosed patients than among those
hospitalized, with differences ranging from 5 (IQVIA-OpenClaims)
to 16% (SIDIAP).
Baseline demographics
The sex distribution (proportions and 95% CIs) of the patients are
reported in Table 1. Aside from VA-OMOP, in the diagnosed cohort,
patients with and without obesity were mostly female. The
proportion of females was higher among PLWO compared to
patients without obesity in SIDIAP (63% vs 56%), CUIMC (61% vs
56%), and IQVIA-OpenClaims (61% vs 52%), while in VA-OMOP the
opposite was observed (13% vs 19%). No differences were observed
in CPRD and STARR-OMOP. In the hospitalized cohort, patients
without obesity were predominantly male (female ranged from 40
to 49%, VA-OMOP: 4%) but PLWO still were more commonly female
in all databases aside from VA-OMOP (range: 51−55%, VA-OMOP:
7%). Differences in the proportion of females between PLWO and
patients without obesity ranged from 3 (VA-OMOP) to 15% (CUIMC).
The age distribution in each database is summarized in Table 1
with proportions and their respective 95% CIs and in Fig. 1 with
histograms. In the diagnosed cohort, PLWO were slightly older
than those without obesity (i.e., the age distribution for PLWO was
slightly skewed to the left compared to patients without obesity).
This was particularly marked in SIDIAP, where 40% of the PLWO
were aged above 65 years and only 20% were so without obesity.
Hospitalized patients were older than those diagnosed. In the
hospitalized cohorts, PLWO were fairly consistently younger than
those without obesity (except for SIDIAP). The proportion of
patients aged above 65 ranged from 36 to 63% for PLWO and
from 43 to 73% for those without obesity.
Baseline medical conditions
We compared baseline medical conditions of PLWO to those of
patients without obesity in the diagnosed and hospitalized cohorts
using SMDs, which are summarized in Fig. 2. We depicted the
SMDs of 485 (CPRD) to 5050 (VA-OMOP) medical conditions in the
diagnosed cohort, and 529 (STARR-OMOP) to 5240 (IQVIA-Open-
Claims) in the hospitalized cohort. In both cohorts, medical
conditions were largely more frequent among PLWO than patients
without obesity.
The distribution of the selected key comorbidities is shown in
Fig. 3, and the proportions with their respective 95% CIs and SMDs
between PLWO and patients without obesity are available in
Supplementary Appendices 4 and 5. In the diagnosed cohorts,
PLWO consistently had a higher prevalence of comorbidities
compared to those without obesity; these differences were
meaningful (i.e., with a SMD > 0.1, which indicates a meaningfully
higher prevalence among PLWO) for the majority of comorbidities
across databases. For example, while the prevalence of hyperten-
sion for PLWO ranged from 30 to 32% in Europe (SIDIAP and
CPRD) and from 55 to 81% in the US, in those without obesity it
ranged from 12 to 16% and from 26 to 53%, respectively. The SMD
for hypertension was above 0.1 in all databases. As in the
diagnosed cohort, PLWO hospitalized with COVID-19 had a higher
prevalence of comorbidities than those without obesity, and these
differences were meaningful for the majority of comorbidities.
However, the differences between groups were less obvious. For
example, heart disease differed by 20% among those diagnosed in
VA-OMOP (PLWO: 60%, without obesity: 40%) and by 9% among
those hospitalized (PLWO: 74%, without obesity: 65%); although
the SMD was still above 0.1 in all databases.
30-day outcomes of interest
The distribution of 30-days outcomes is shown in Fig. 4, the
proportions with their respective 95% CI and SMDs between
PLWO and patients without obesity are available in Table 2. In the
diagnosed cohorts, hospitalization rates were higher among PLWO
than among those without obesity in all databases. For example,
in SIDIAP the proportion of patients hospitalized was 20% for
PLWO and 10% for patients without obesity. However, these
differences were meaningful (SMD > 0.1) only in three databases:
SIDIAP, CUIMC, and STARR-OMOP. In PLWO, fatality ranged from 5
to 12% and was higher than in patients without obesity in SIDIAP
and CUIMC (7% vs 3% and 8% vs 5%, respectively), while in CPRD
and VA-OMOP it was similar in both groups. SIDIAP was the only
database with a meaningful difference in the proportion of fatality.
Overall, in the hospitalized cohort, PLWO more frequently had
adverse events occurring in the 30 days after the index date than
patients without obesity. For example, PLWO required IS and
presented with ARDS more frequently than patients without
obesity in the largest databases: IQVIA-OpenClaims (IS: 13% vs
10%; ARDS: 35% vs 31%) and VA-OMOP (IS: 22% vs 15%; 46% vs
41%), whereas in CUIMC and STARR-OMOP percentages were
similar. VA-OMOP was the only database with a meaningful
Fig. 1 Distribution of age among patients living with and without obesity in each database, stratified by COVID-19 cohort type
(diagnosed and hospitalized). CPRD Clinical Practice Research Datalink, COVID-19 coronavirus disease 2019, CUIMC Columbia University
Irving Medical Center, SIDIAP Information System for Research in Primary Care, STARR-OMOP Stanford Medicine Research Data Repository, VA-
OMOP United States Department of Veterans Affairs.
M. Recalde et al.
4
International Journal of Obesity
difference in the proportion of IS. Similarly, heart failure was also
more frequent among PLWO than among patients without
obesity in CUIMC: 7% vs 3%, IQVIA-OpenClaims: 7% vs 5%,
STARR-OMOP: 16% vs 9%, and VA-OMOP: 23% vs 17%), these
differences were meaningful in CUIMC and STARR-OMOP. Sepsis,
cardiac arrhythmia, and cardiovascular disease events were
slightly more frequent among PLWO, although SMDs were below
0.1 in all databases. Acute kidney injury was the only outcome
that was more frequent among patients without obesity;
however, this difference was not meaningful in any database.
Fig. 3 Comorbidities at baseline among patients living with obesity compared to patients living without obesity in each database,
stratified by COVID-19 cohort type (diagnosed and hospitalized). Prevalence of comorbidities for COVID-19 patients living with obesity (red)
and without obesity (blue) are depicted in overlapped horizontal bars. The gray color is the overlap between groups. E.g., in CPRD, 32% of
COVID-19 patients living with obesity and 16% living without obesity have hypertension. Comorbidities with a meaningful difference (|SMD| >
0.1) between patients living with and without obesity are marked with an asterisk (*). COPD chronic obstructive pulmonary disease, COVID-19
coronavirus disease 2019, CPRD Clinical Practice Research Datalink, CUIMC Columbia University Irving Medical Center, SIDIAP Information
System for Research in Primary Care, SMD standardized mean difference, STARR-OMOP Stanford Medicine Research Data Repository, VA-
OMOP United States Department of Veterans Affairs.
Fig. 2 Standardized mean differences in conditions among patients living with obesity compared to patients living without obesity in
each database, stratified by COVID-19 cohort type (diagnosed and hospitalized). SMD < 0 means the prevalence was greater in COVID-19
patients living without obesity, SMD > 0 means the prevalence was greater in COVID-19 patients living with obesity. COVID-19 coronavirus
disease 2019, CPRD Clinical Practice Research Datalink, CUIMC Columbia University Irving Medical Center, SIDIAP Information System for
Research in Primary Care, SMD standardized mean difference, STARR-OMOP Stanford Medicine Research Data Repository, VA-OMOP United
States Department of Veterans Affairs.
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As for fatality, there were no consistent nor meaningful
differences between PLWO and patients without obesity in the
hospitalized cohort: while it was higher for PLWO in SIDIAP (14%
vs 11%), there were no differences in CUIMC (20% vs 21%) nor in
VA-OMOP (16% vs 18%).
DISCUSSION
In this large cohort study including 627 044 COVID-19 patients
from Spain, the UK, and the US, we found that the prevalence of
obesity was higher among COVID-19 patients hospitalized (40%)
compared to those diagnosed (31%). PLWO diagnosed and
hospitalized with COVID-19 were more commonly female, and
those hospitalized were younger than patients without obesity.
The extraction of more than 15 000 medical conditions revealed
PLWO were not only more prone to have obesity-related
comorbidities, such as hypertension, heart disease, and type 2
diabetes but also to more than a thousand different health
conditions. After 30-days of follow-up, PLWO presented with
higher hospitalization rates and intensive services requirements,
although these differences were only meaningful in some
databases.
Our study has several strengths, such as its large amount of
data. By bringing together harmonized data using a federated
approach, we have conducted a large-scale study while respecting
the confidentiality of patient records. The international approach
of this study is a strong asset given that we are investigating the
intersection of two major global threats, namely the obesity
epidemic and the COVID-19 pandemic. The former, together with
the diverse healthcare settings and populations described in this
study, increase the generalizability of our findings. Further, we
provide a wide overview of the characteristics and outcomes of
patients with and without obesity, using data visualization tools to
summarize large amounts of medical data. This exhaustive
characterization goes far beyond prior studies reporting few
comorbidities and supports the generation of new hypotheses
that can be tested in future studies. In addition, for the sake of
transparency and reproducibility, we have made methods, tools,
and all results publicly available. As CHARYBDIS is an ongoing
study, results (included longer follow-up time) will be updated and
new studies focussing on obesity could be conducted. All of the
above has been accomplished through the coordinated efforts of
the OHDSI community to provide a rapid response to the COVID-
19 pandemic.
Our study also has limitations. First, we cannot exclude a
selection bias of COVID-19 cases due to underreporting in the
context of testing restrictions and asymptomatic or paucisympto-
matic cases that usually do not seek medical care. Additionally,
testing policies have varied across countries and time depending
on the course of the pandemic. Nevertheless, the inclusion of
patients clinically diagnosed (not tested) in different settings likely
provided consistency to our data, although it might have incurred
in false positives. Second, we did not have information on BMI as a
continuous variable, which prevented us from investigating the
impact of different categories of obesity in COVID-19 outcomes.
This might explain the higher proportion of comorbidities and
outcomes observed in the US databases, as PLWO from the US
might have higher BMIs than those from Europe [20]. In addition,
our definition of obesity included diagnoses and measurements
recorded at any time prior to or at the index date, and therefore
some individuals might have been misclassified due to changes in
BMI since the most recently recorded status. However, previous
evidence shows that BMI trajectories in adults are relatively stable,
with a tendency to increase with age [21]. Therefore adults with
obesity are likely to still have obesity over time. Finally, this study
was underpinned by routinely collected data which can raise
concerns about the quality of the data. Some databases are prone
to oversampling certain groups of people as a result of how these
Fig. 4 A comparison of 30-day events among patients living with and without obesity in each database, by COVID-19 cohort type
(diagnosed and hospitalized). Proportion of outcomes for COVID-19 patients living with obesity (red) and without obesity (blue) are depicted
in overlapped horizontal bars. The gray color is the overlap between groups. E.g., in the diagnosed cohort, 20 and 10% of patients living with
and without obesity in SIDIAP, respectively, were hospitalized. Outcomes with a meaningful difference (|SMD| > 0.1) between patients living
with obesity and patients without obesity are marked with an asterisk (*). ARDS acute respiratory distress syndrome, COVID-19 coronavirus
disease 2019, CPRD Clinical Practice Research Datalink, CUIMC Columbia University Irving Medical Center, SIDIAP Information System for
Research in Primary Care, SMD standardized mean difference, STARR-OMOP Stanford Medicine Research Data Repository, VA-OMOP United
States Department of Veterans Affairs.
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data are captured (e.g., the Veterans Affairs system historically
serves more men than women, routine claims data may only
reflect health outcomes in commercially insured populations, etc.).
Obesity, comorbidities, and outcomes were assessed based on
having a record of a condition/measurement, therefore they may
be underestimated. In addition, outcomes such as hospitalization
or intensive services requirements are also influenced by factors
external to the patient’s condition (i.e., bed availability, criteria for
admission), which might differ across databases. Even still, the
consistency of our findings across databases that differ by setting
and country lends credence to the generalizability of our findings.
Given the prevalence of obesity in Spain (24%), the UK (27%),
and the US (37%), a high proportion of PLWO among COVID-19
cases was expected [20]. However, the prevalence of obesity
among diagnosed COVID-19 patients was higher than the general
population in four databases: SIDIAP (Spain): 30%; CPRD (UK): 42%;
CUIMC and VA-OMOP (US): 41 and 47%, respectively, which is
suggestive of an increased risk of diagnosis in PLWO. In addition,
the prevalence of obesity was higher in hospitalized COVID-19
patients, with an overall prevalence of obesity of 40%, which is in
line with three cohort studies from the US that reported that 40,
42, and 48% of inpatients were living with obesity [17, 22, 23]. A
large meta-analysis of observational studies reported that obesity
is associated with a higher risk of testing positive for SARS-CoV-2
or being diagnosed with COVID-19 as well as of being hospitalized
with COVID-19 [7]. While this could be due to an increased
vulnerability to SARS-CoV-2 in PLWO, other hypotheses should be
considered in future studies. On the one hand, individuals with
obesity could be more likely to seek care and be tested for SARS-
CoV-2 since they are (presumably) a high-risk population, have
multiple comorbidities, and are more prone to respiratory
symptoms due to their compromised pulmonary function [2, 7].
On the other hand, given the fact that obesity disproportionately
affects disadvantaged populations, potential differential expo-
sures across subpopulation groups should also be explored
(e.g., differential occupational risks) [2].
Women predominated among hospitalized patients with
obesity, even though obesity rates are similar in both sexes in
the three countries [20]. Although male sex is a well-established
risk factor for COVID-19-related hospitalization and death, little is
known about the role of obesity on COVID-19 outcomes stratified
by sex [14, 23–25]. Recent studies addressing this issue in
secondary analyses have reported inconsistent results. A study
conducted among UK Biobank participants found that the impact
of BMI in COVID-19-related death was higher among females
compared to men, while others have found a higher effect among
males, opposite effects of sex in different age strata or null
differences [26–29]. Thus, the intersection between sex/gender
and obesity in relation to COVID-19-outcomes warrants further
investigation. Because sex-stratification was beyond the pre-
specified analysis plan of our study, we were unable to report
our results by sex, which could have provided valuable insights on
the matter. We intend, however, to address this issue in upcoming
studies from the CHARYBDIS project.
We also found that hospitalized PLWO were younger than those
without obesity. Although younger individuals have less risk of
infections and complications than older people due to having
fewer comorbidities and a stronger immune system, this is not the
case for those with obesity [2, 7, 30–32]. Some authors have
postulated that PLWO younger than 60 years could have a greater
risk of severe COVID-19 outcomes [33]. PLWO also had many more
comorbidities than patients without obesity. Unsurprisingly, the
highest differences were observed in obesity-related conditions,
such as hypertension, diabetes, and heart disease, which have
been identified as risk factors for severe COVID-19 outcomes
[14, 17, 25, 34, 35]. However, as our findings revealed, PLWO with
COVID-19 differ from patients without obesity in a wider range of
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studies aiming to disentangle the effect of obesity in COVID-19
outcomes should have this information present and consider data-
driven techniques to account for confounding, such as propensity
score estimation and its adjustment methods [18].
Finally, PLWO experienced adverse events more frequently than
those without obesity, particularly hospitalization and the require-
ment of intensive services. Certainly, our results must be interpreted
carefully considering the differences in demographics and comor-
bidities between these groups. Interestingly, in patients hospita-
lized, we did not observe clear differences in fatality between
patients with and without obesity. While two meta-analyses
reported that obesity is associated with a higher risk of COVID-19
related mortality; other large observational studies from the US and
the UK using finer categories of BMI only found an association
with mortality for morbid obesity (BMIs ≥ 35 kg/m2 or ≥40 kg/m2)
[7, 25, 28, 29, 34]. Given the scarcity of evidence regarding the
frequency of specific adverse events during hospitalization among
PLWO, our findings are of special interest to the field and should be
addressed in upcoming etiological studies.
In this large international cohort, we showed that among
COVID-19 cases, PLWO were more likely to be female, have more
comorbidities, and worse outcomes than patients without obesity.
The prevalence of obesity was higher among hospitalized patients
with COVID-19 compared to patients diagnosed with COVID-19.
Our results may be useful in guiding clinical practice and aid
future preventative strategies for patients living with obesity, as
well as providing useful data to support subsequent etiological
studies focussed on obesity and COVID-19.
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